GlassScriptPhysician profile
Wa'El Bakdash
NPI 1275552481
$8,086.30
in general payments reported to CMS, 2019-2025
39 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,038 · 2020: $485 · 2021: $46.02 · 2022: $1,434 · 2023: $1,357 · 2024: $1,651 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,083.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,511.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $816.31 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $713.01 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $702.60 | 2019-2025 | Vraylar, Teflaro, Dalvance |
| Lilly USA, LLC | $660.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $458.77 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $330.83 | 2019-2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $278.31 | 2019-2024 | Xarelto, Spravato |
| Glaxosmithkline, LLC. | $275.24 | 2019-2023 | Shingrix, Arexvy |
| Amgen INC. | $253.81 | 2019-2025 | Evenity, Repatha, Otezla |
| Amarin Pharma, INC. | $223.78 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $190.57 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.09 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $166.79 | 2023-2025 | Voquezna |
| Jazz Pharmaceuticals INC. | $153.86 | 2019-2024 |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wa'El Bakdash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.